Entrada Therapeutics (TRDA) CEO Dipal Doshi Sells 8,724 Shares

What Happened Dipal Doshi, CEO and director of Entrada Therapeutics, reported the disposition of 8,724 shares on September 2, 2026. The Form 4 lists a weighted average sale price of $7.14 per share for total proceeds of $62,323. This was a sale (not a purchase) executed to satisfy tax-withholding obligations tied to an award.

Key Details

• Transaction date: 2026-09-02; Form 4 filed: 2026-09-03 (timely).
• Shares sold: 8,724; reported weighted average price: $7.14; total value reported: $62,323.
• Footnote F1: Sale was automatic under a mandatory sell-to-cover provision to cover minimum statutory tax withholding — not a discretionary trade by the insider.
• Footnote F2: The $7.14 is a weighted average; actual sale prices ranged from $6.97 to $7.34. Detailed per-price breakdown is available on request per the filer.
• Transaction code: F (tax withholding). Shares owned after the transaction are not specified in the provided summary.

Context This was a routine, non-discretionary sell-to-cover tied to an award agreement (common when equity vests or options are exercised). Such mandatory sales are done solely to meet tax obligations and generally should not be read as an active vote on company prospects by the insider.